Browse Studies — Arctuva

Phase 4

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduc…

GlaucomaOpen-Angle GlaucomaOcular Hypertension+1 more

Estimated

~$10 – $6,250

University of MiamiNCT07217678

Real-World Efficacy of Hydrus Microstent With OMNI Surgical System in Combination With Phacoemulsification: a Retrospective Analysis

Real-World efficacy of Hydrus Microstent with OMNI Surgical System in combination with Phacoemulsification: a retrospective analysis

Open-Angle Glaucoma

Estimated

~$10 – $1,125

Barnet Dulaney Perkins Eye CentersNCT06953349

Observational

A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma

This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Bo…

Open-angle Glaucoma (OAG)Ocular Hypertension (OHT)

Estimated

~$10 – $6,250

Medical University of South CarolinaNCT07408154

Phase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Open-angle GlaucomaOcular Hypertension

Estimated

~$10 – $8,750

Amneal Pharmaceuticals, LLCNCT06267274